Catalyst
Slingshot members are tracking this event:
Top-line data for the Phase 2 CLARITY trial of Pimavanserin in Adjunctive Treatment, in Patients With Major Depressive Disorder due 2H 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ACAD | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 27, 2018
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pimavanserin, Major Depressive Disorder
